Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Apr;79(4):651-660.
doi: 10.1007/s00280-016-3237-x. Epub 2017 Mar 11.

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

Naoya Yamazaki  1 , Tatsuya Takenouchi  2 , Manabu Fujimoto  3 , Hironobu Ihn  4 , Hiroshi Uchi  5 , Takashi Inozume  6 , Yoshio Kiyohara  7 , Hisashi Uhara  8 , Kazuhiko Nakagawa  9 , Hiroshi Furukawa  10 , Hidefumi Wada  11 , Kazuo Noguchi  12 , Takashi Shimamoto  12 , Kenji Yokota  13
Affiliations
Clinical Trial

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

Naoya Yamazaki et al. Cancer Chemother Pharmacol. 2017 Apr.

Abstract

Purpose: This phase I b study evaluated the safety and anti-tumor activity of pembrolizumab in Japanese patients with advanced melanoma.

Methods: Pembrolizumab (2 mg/kg) was given every 3 weeks (Q3W) for up to 2 years or until confirmed progression or unacceptable toxicity. The tumor response was assessed as per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by both investigator review and central review.

Results: Forty-two patients with advanced melanoma received pembrolizumab. A primary cutaneous histology was observed in 34 patients (81.0%), while a primary mucosal histology was observed in 8 patients (19.0%). Thirty-four patients (81.0%) experienced treatment-related adverse events (AEs). The most common treatment-related AEs were pruritus, maculopapular rash, malaise, and hypothyroidism. Grade 3-5 treatment-related AEs occurred in 8 patients (19.0%). The only grade 3-5 treatment-related AE reported in at least two patients was anemia. There were two treatment-related deaths (unknown cause and cerebral hemorrhage). Among the 37 evaluable patients, the confirmed overall response rates (ORRs) determined by central review were 24.1% (95% CI 10.3-43.5) for cutaneous melanoma and 25.0% (95% CI 3.2-65.1) for mucosal melanoma. The responses were durable, and the median duration of response was not reached in either population. The median overall survival (OS) was not reached, with a 12-month OS of 82.7% for cutaneous melanoma and 51.4% for mucosal melanoma.

Conclusion: The safety profile of pembrolizumab in Japanese patients was similar to that reported in the previous clinical studies. Pembrolizumab provided promising anti-tumor activity in Japanese patients with advanced melanoma.

Keywords: Anti-PD-1 therapy; Immunotherapy; Japanese patients; Melanoma; Pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

Funding

This study was funded by MSD K.K. (Tokyo, Japan).

Conflict of interest

K. Nakagawa received a speaker honoraria from Astellas, AstraZeneca, EPS Holdings, Ono Pharmaceutical, Kyowa Hakko Kirin, Showa Yakuhin Kako, SymBio Pharmaceuticals, Daiichi Sankyo, Chugai Pharmaceutical, Nippon Boehringer Ingelheim, Eli Lilly Japan, Pfizer Japan, and Bristol-Myers Squibb, and received research grants funding from Chugai Pharmaceutical, MSD, Ono Pharmaceutical, EPS Associates, Quintiles, Daiichi Sankyo, Japan Clinical Research Operations, Eisai, PPD-SNBL, Pfizer Japan, Takeda Pharmaceutical, Nippon Boehringer Ingelheim, Taiho Pharmaceutical, and Bristol-Myers Squibb. H. Uhara received a speaker honorarium from MSD, Ono Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Novartis Pharma, Roche Diagnostics, and Mochida Pharmaceutical, and received research grants from Ono Pharmaceutical, Chugai Pharmaceutical, and Mochida Pharmaceutical. T. Takenouchi received a speaker honorarium from MSD, Ono Pharmaceutical, and Bristol-Myers Squibb, Chugai Pharmaceutical, and Novartis Pharma. Y. Kiyohara received research grants from Ono Pharmaceutical, Chugai Pharmaceutical, Bristol-Myers Squibb, MSD, Merck Serono, GlaxoSmithKline, and received a speaker honorarium from Ono Pharmaceutical, and Chugai Pharmaceutical, and reported the safety review committee role of Ono Pharmaceutical, and Chugai Pharmaceutical. T. Shimamoto and K. Noguchi are employees of MSD K.K. and hold stock in Merck & Co., Inc., Kenilworth, NJ, USA. N. Yamazaki, M. Fujimoto, H. Ihn, H. Uchi, T. Inozume, H. Furukawa, H. Wada, and K. Yokota declare that they have no conflict of interest.

Ethical standards

The study was performed in accordance with the ethical standards established in the 1964 Declaration of Helsinki and its later amendments. The study was approved by the institutional review board of each study site, and all the patients provided informed consent prior to their inclusion in the study.

Figures

Fig. 1
Fig. 1
Anti-tumor activity of pembrolizumab per RECIST v1.1 by central review. a Best change from baseline in the sum of the longest target lesion diameters for each patient. b Treatment exposure and duration of response per patient. c Longitudinal changes in the sum of the longest target lesion diameters for each patient
Fig. 2
Fig. 2
Kaplan–Meier analysis of a progression-free survival per RECIST v1.1 by central review and b overall survival
See this image and copyright information in PMC

References

    1. Kibbi N, Kluger H, Choi JN. Melanoma: Clinical Presentations. Cancer Treat Res. 2016;167:107–129. doi: 10.1007/978-3-319-22539-5_4. - DOI - PubMed
    1. Spencer HL, Mehnert JM. Mucosal Melanoma: Epidemiology, Biology and Treatment. Cancer Treat Res. 2016;167:295–320. doi: 10.1007/978-3-319-22539-5_13. - DOI - PubMed
    1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 - PubMed
    1. Jemal A, Bray F, Center MM. Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107. - DOI - PubMed
    1. Ishihara K, Saida T, Otsuka F, Yamazaki N, et al. Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol. 2008;13:33–41. doi: 10.1007/s10147-007-0751-1. - DOI - PubMed

Publication types

MeSH terms